NCT00130247 - Tuberculosis Treatment Shortening Trial | Biotech Hunter

Enrollment

394

Participants

Timeline

Start Date

April 8, 2002

Primary Completion Date

September 2, 2008

Study Completion Date

November 28, 2008

Conditions

Tuberculosis

Interventions

DRUG

Ethambutol

Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).

DRUG

Isoniazid

Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.

DRUG

Pyrazinamide

1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.

DRUG

Rifampin

1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).

Trial Locations (3)

1229

Makati Medical Center, Makati City

99999

Mulago Hospital Complex, Kampala

29040-091

Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH